Forward-looking statements caution that results and timelines are subject to risks and uncertainties and are not guarantees of future performance.

Cytovance has two decades of experience as a CDMO, offering integrated services from molecule development to potential commercial manufacturing.

Analysts’ view includes a price target near $10, a price-to-book around 5.72, and an RSI in the high-30s, with substantial institutional and insider ownership suggesting confidence amid volatility.

Financial indicators show no current revenue, negative earnings per share, a very strong current ratio, minimal debt, and insider buying of 10,000 shares signaling management confidence.

The company is moving into Phase 2 based on Phase 1 data, with near-term updates on development progress anticipated.

The vaccine program was developed in collaboration with the Cleveland Clinic, drawing on work led by the late Vincent Tuohy, and reflects Anixa’s strategy of partnering with leading research institutions.

The press release lays out Anixa’s broader vaccine portfolio, ongoing collaborations with Cleveland Clinic and Moffitt Cancer Center, and standard forward-looking disclosures.

Anixa Biosciences advances its breast cancer vaccine to Phase 2 after positive Phase 1 results and signs a development and manufacturing deal with Cytovance Biologics to produce cGMP clinical materials.

In Phase 1, the vaccine elicited protocol-defined immune responses in about three-quarters of participants, signaling robust immunogenic activity.

Cytovance Biologics, a longtime CDMO for mammalian and microbial production, will supply the cGMP materials needed for the Phase 2 study.

Market reaction to the news showed roughly a 6% jump in the stock price as investors expressed optimism about the development milestone.

Anixa operates in oncology, focusing on Cancer Vaccines and CAR-T Therapies, with a market capitalization near $86.5 million and about 33.5 million shares outstanding.